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A b s t r a c t
“Cirrhosis” is a morphologic term that has been 
used for almost 200 years to denote the end stage of 
a variety of chronic liver diseases. The term implies a 
condition with adverse prognosis due to the well-known 
complications of portal hypertension, hepatocellular 
carcinoma, and liver failure. However, recent 
advances in the diagnosis and treatment of chronic 
liver diseases have changed the natural history of 
cirrhosis significantly. This consensus document by the 
International Liver Pathology Study Group challenges 
the usefulness of the word cirrhosis in modern 
medicine and suggests that this is an appropriate time 
to consider discontinuing the use of this term. The 
role of pathologists should evolve to the diagnosis of 
advanced stage of chronic liver disease, with emphasis 
on etiology, grade of activity, features suggestive of 
progression or regression, presence of other diseases, 
and risk factors for malignancy, within the perspective 
of an integrated clinicopathologic assessment.
Definition and Current Understanding 
of Cirrhosis
“Cirrhosis” derives from the Greek word κίρρος, mean-
ing tawny, and was initially used to describe the gross (tawny, 
nodular, and firm) and, afterwards, the microscopic appear-
ance of the chronically diseased and physiologically burned 
out and dysfunctional liver.1,2 For almost 2 centuries, the 
emphasis was placed on the irreversible, “end-stage” nature 
of these livers; etiology was not considered very important 
because there was no cure, and survival was usually short. In 
1977, an international panel, sponsored by the World Health 
Organization, defined cirrhosis as “a diffuse process charac-
terized by fibrosis and the conversion of normal liver archi-
tecture into structurally abnormal nodules.”3 The panel also 
noted that “cirrhosis is a chronic progressive condition that 
results in liver cell failure and portal hypertension.” Further-
more, the panel stated that vascular abnormalities were a very 
important feature of cirrhosis. The latter include thrombosis, 
obliteration, and recanalization of veins; formation of arterio-
venous shunts; and “capillarization” of sinusoids.4
The natural history of cirrhosis has changed significantly 
in recent years, as therapeutic advances in the field of chronic 
liver diseases allow patients with cirrhosis to survive long-
term, often with their conditions improving clinically and 
histologically, in the course of time. Therefore, it is becoming 
obvious that, by modern standards, all cases of cirrhosis do 
not inevitably “result in liver cell failure and portal hyperten-
sion.” Furthermore, the possibility of regression of cirrhosis 
has been considered5 and is now thought likely by several 
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investigators. From a practical viewpoint, a need to redefine 
cirrhosis as a pathologic condition that evolves through more 
than one stage has been acknowledged.6
Using a morphology-based unitary term, such as cir-
rhosis, for a part of the evolutionary spectrum of a variety 
of diseases is unusual in modern medicine because disease 
classification, diagnosis, and treatment are primarily based 
on etiology. Indeed, it is difficult to find any term referring 
to a pathologic condition of other organs that is conceptually 
similar to cirrhosis of the liver. Furthermore, the concept of 
cirrhosis as an end-stage and irreversible process is so widely 
known to the public that the implication of the word itself is 
often problematic.
Recent discussions by the International Liver Pathology 
Study Group (San Francisco, CA, 2009, and London, Eng-
land, 2010) have suggested that this is an appropriate time to 
consider discontinuing use of the word cirrhosis. The role of 
pathologists should evolve to the diagnosis of advanced stage 
of chronic liver disease, with emphasis on etiology, grade 
of activity, features suggestive of progression or regression, 
presence of other diseases, and risk factors for malignancy, 
within the perspective of an integrated clinicopathologic 
assessment. The current article elaborates on this suggestion.
Cirrhosis and Cirrhoses
Cirrhosis is a heterogeneous condition with differing 
clinical manifestations and prognosis depending on the etiol-
ogy and the severity of hepatic architectural distortion. The 
main causes of cirrhosis include chronic hepatitis B, chronic 
hepatitis C, autoimmune hepatitis, fatty liver diseases, chronic 
biliary diseases, and several inherited metabolic disorders.4,7 
Each one of these diseases has a relatively well-understood 
natural history and may cause significant liver injury, accom-
panied over time by regeneration, scarring, and vascular 
alterations, leading to an advanced stage characterized by 
nodularity and fibrous septation. Many of them now have 
specific therapies not available in the past.
Different etiologies cause different patterns of scarring 
and regeneration and have different rates of progression. 
Furthermore, within each disease entity, the magnitude of 
architectural distortion and the resultant clinical implications 
vary in severity among patients and over time. The clinical 
spectrum of cirrhosis is indeed wide, ranging from patients 
who feel no burden in their regular daily activities (a typical 
scenario with cirrhosis secondary to nonalcoholic steatohepa-
titis, for example) to severely ill patients with complications 
such as portal hypertension, hepatic encephalopathy, and 
hepatocellular carcinoma. On the other hand, there are simi-
larities among cirrhotic livers of different etiologies extending 
all the way to the cellular level, reflecting common pathogenic 
mechanisms: stellate cells and fibroblasts are the effectors of 
fibrogenesis, while parenchymal regeneration relies on hepa-
tocytes and hepatic stem/progenitor cells.8,9
Until recently, fibrosis occurring in chronic liver diseas-
es was considered a relentless process that could sometimes 
be halted but would not regress. However, modern treat-
ment of chronic liver diseases has made clear that hepatic 
fibrosis can regress over time. Depending on the type of 
disease, successful treatment may involve eradication of a 
virus (eg, chronic hepatitis C)10; control of the inflammatory 
process following inhibition of viral replication (eg, chronic 
hepatitis B)11 or suppression of autoimmunity (autoimmune 
hepatitis)12; and removal of the offending agent (eg, alcohol, 
iron13). Regression of fibrosis may take place in precirrhotic 
and cirrhotic livers.5
In recently published series regarding patients with 
chronic viral hepatitis undergoing treatment, there are subsets 
of patients with cirrhosis who show significant histologic 
improvement (in necroinflammatory activity and fibrosis) in 
repeated biopsies.10,11,14 Although regression of cirrhosis may 
indeed occur in some patients,15-17 evolution to incomplete 
septal cirrhosis (a condition that, despite its name, does not 
meet the criteria for the traditional definition of cirrhosis) 
has been suggested as a likely explanation for others.5 In 
such cases, incomplete septal cirrhosis may result from thin-
ning and loss of the fibrous septa surrounding the nodules 
(ie, regression of fibrosis), with persistence of at least some 
degree of the vascular changes characteristic of cirrhosis (eg, 
arteriovenous shunts, portal vein branch obliteration). Mak-
ing this diagnosis in any particular case may have significant 
clinical implications, as patients with incomplete septal cir-
rhosis may not require orthotopic liver transplantation, as 
many patients with cirrhosis do, but may instead benefit from 
a vascular shunting procedure.
A Contemporary Approach for the Assessment 
of Advanced Chronic Liver Diseases
At present, there is increasing recognition of the need for 
a pathophysiologic staging of cirrhosis that will incorporate 
the clinical, histologic, and hemodynamic findings of each 
particular patient.6 For example, the hepatic venous pressure 
gradient (HVPG) is emerging as an important parameter of a 
proposed classification6 because HVPG levels have a good 
correlation with the complications of portal hypertension. 
As HVPG measurements are not widely available, surrogate 
histologic markers of this parameter would be desirable. 
For example, there is evidence that small parenchymal nod-
ules and thick fibrous septa are associated with increased 
HVPG.18,19 Therefore, the thickness of the fibrous septa 
has been suggested as a tool to stage advanced chronic liver 
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disease.18,20 Furthermore, a significant correlation between 
HVPG and collagen proportionate area, a novel marker of 
fibrosis that can be assessed in histologic material by image 
analysis, has been found.21 In addition, liver stiffness mea-
surement, assessed by transient elastography, a noninvasive 
method, has been found to be in excellent correlation with 
HVPG values up to the level of 10 to 12 mm Hg in patients 
with chronic hepatitis C.22,23
We consider this pathophysiologic approach entirely 
appropriate for the present, but we suggest that it is applied to 
each advanced chronic liver disease independent of the term 
cirrhosis. For example, a pathologist examining a liver biopsy 
specimen from a patient with chronic hepatitis B may simply 
state that the patient has chronic hepatitis B of advanced stage 
(eg, corresponding to the descriptions for stages 5 and 6 of 
the Ishak staging system24), without using the word cirrhosis 
❚Figure 1❚. The pathology report should also include the grade 
of necroinflammatory activity and a statement regarding risk 
factors for hepatocellular carcinoma (such as small cell change 
and large cell change), if present. This information should be 
sufficient for providing appropriate treatment and follow-up. 
Whether the advanced stage seen in the biopsy material actu-
ally represents end-stage liver disease will be determined 
by clinicopathologic correlation and response to treatment. 
Treatment adjustments can then be decided on the basis of the 
clinical course and subsequent biopsies, as needed.
This proposal emphasizes the etiology of liver disease in 
each case and has the advantage that each disease process is 
addressed without the negative connotations of irreversibility 
and end-stage nature that have traditionally been associated 
with the word cirrhosis. Furthermore, our approach acknowl-
edges the fact that histologic examination alone is insufficient 
to document liver disease that is likely to be irreversible, while 
clinical assessment of advanced chronic liver disease without 
histologic support may not differentiate between the various 
causes of portal hypertension (eg, advanced chronic liver dis-
ease due to virus or steatohepatitis vs hepatoportal sclerosis). 
In addition, this etiology-based approach may facilitate the 
development of new screening strategies for early detection of 
hepatocellular carcinoma because there are significant differ-
ences in the incidence of this neoplasm among chronic hepatic 
diseases of differing etiologies.
In some cases of advanced chronic liver disease, histolog-
ic features indicative of fibrosis resorption and architectural 
improvement may be detected over time. The detection of his-
tologic features suggestive of regression may represent useful 
information, with therapeutic and prognostic implications. 
Wanless et al5 provided a detailed account of such regressive 
changes, which they termed “hepatic repair complex.” These 
include delicate, perforated fibrous septa; isolated, thick col-
lagen fibers; delicate periportal fibrous spikes; portal tract 
remnants; hepatic vein remnants with prolapsed hepatocytes; 
❚Figure 1❚ A contemporary approach for the assessment of advanced chronic liver diseases. The stage is determined or 
confirmed by liver biopsy. The final diagnosis is derived from clinicopathologic correlation (assisted by follow-up, as needed), 
and includes the etiology, the stage, the activity of the disease process, and risk factors for malignancy. HVPG, hepatic venous 
pressure gradient.
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chronic liver disease
Liver biopsy showing advanced stage
of chronic liver disease
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-Activity of disease process
-Features of regression
-Presence of other diseases
-Risk factors for malignancy
-Surrogate markers of HVPG
Final diagnosis, including:
Etiology of chronic liver disease
Stage (3 clinically relevant possibilities):
-Advanced stage (not otherwise specified)
-Advanced stage with features of regression
-End stage
Activity of disease process
Risk factors for malignancy
Follow-up
Clinical workup
Assessment of etiology,
by laboratory and/or
radiologic methods,
as appropriate
Assessment of severity
(laboratory tests,
transient elastography,
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hepatocytes within portal tracts or splitting septa; minute 
regenerative nodules; and aberrant parenchymal veins.5 
Additional studies may further clarify the histologic fea-
tures that are predictive of progression or regression of 
each chronic liver disease, thus aiding clinicians in patient 
management.
Putting Our Proposal Into Practice
Terminology changes are difficult to accomplish, espe-
cially for medical terms in widespread use, such as the 
word cirrhosis. Although the contemporary approach for 
the assessment of advanced chronic liver diseases delin-
eated herein clearly suggests that this term has outlived its 
usefulness, wide consensus of pathologists and clinicians 
will be required for such a terminology change to become 
successful. This process may take some time to materialize. 
In the meantime, physicians involved in the diagnosis and 
treatment of liver diseases may explore the benefits of the 
recommended change.
In each patient with chronic liver disease, identifica-
tion of the etiology and determination of stage are the 2 
most important factors regarding prognosis and treatment. 
Determination of stage should be disease-specific (ie, the 
same staging system is not applicable for all diseases) but is 
often difficult to accomplish with accuracy in a small biopsy 
specimen, which is one more reason why a combined clini-
copathologic approach seems more reasonable.25 Keeping 
in mind that staging systems reflect the knowledge and the 
needs of the period when each of them was invented, our 
proposal may be considered as a starting point for a fresh 
look at staging chronic liver diseases in the era of regress-
ing fibrosis.
Therefore, we recommend replacing the word cirrhosis 
with the term “advanced stage,” when reporting the diagno-
sis of chronic liver diseases. Advanced stage includes cases 
previously diagnosed as cirrhosis, but also those with sig-
nificant fibrosis and architectural distortion, which fall short 
of traditional cirrhosis. In cases with regression of fibrosis 
and architectural improvement, the term “advanced stage 
with features of regression” is appropriate. Assessment of 
fibrosis regression in biopsy material is not an easy task for 
practicing pathologists at present; this is best accomplished 
when previous biopsy specimens from the same patient 
are available for comparison. For cases of advanced-stage 
chronic liver disease with clinically significant portal 
hypertension, the term “end stage” may be appropriate. 
Obviously, carefully designed clinicopathologic studies 
will be needed to address the definition of end stage in each 
chronic liver disease. Until then, it is reasonable to associ-
ate end stage with an HVPG of 10 to 12 mm Hg or more, 
representing a critical threshold beyond which chronic liver 
disease becomes a systemic disorder with involvement of 
other organs and systems.6,26
Some examples of how to use these diagnostic terms in 
pathology reporting include the following: (1) liver biopsy: 
autoimmune hepatitis, advanced stage, with severe activity; 
(2) liver biopsy: chronic hepatitis C, advanced stage, with 
moderate activity, and large cell change of hepatocytes; 
(3) liver biopsy: chronic hepatitis B, advanced stage, with 
features of regression, without activity; and (4) liver biopsy: 
nonalcoholic steatohepatitis, advanced stage (clinically, end 
stage), with mild activity.
Conclusion
We propose that use of the word cirrhosis should be 
discontinued and that each patient with chronic liver dis-
ease of advanced stage should be provided treatment on the 
basis of clinicopathologic correlation of all available find-
ings (Figure 1). This proposal is consistent with our current 
understanding of the evolution of chronic liver diseases 
and will also remove an unnecessary psychological burden 
from patients. In addition, research into the pathogenesis 
and evolution of chronic liver diseases will be facilitated 
if an etiology-based perspective extends all the way to the 
end stage. In the past, ignorance was a good reason to lump 
the advanced stages of different liver diseases together; the 
opposite may prove to be more useful in the future.
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